ClinicalTrials.gg
RecruitingNCT04110067Updated Nov 18, 2026

Clinical Results of Small Incision Lenticule Extraction (SMILE) for the Correction of High Myopia

An observational study in Myopia and High Myopia, sponsored by Suphi Taneri. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Suphi Taneri · Observational

How we know

From the registry’s dates

  • Started Jan 2016; still recruiting 10 years 10 months later.
Updated Nov 18, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Myopia with a site in Germany — 3 open to participants now, 4 under way, 1 of them phase 3. Myopia · Germany.

Started
2016
the only one that year
Observational
5 of 16
1 open now
Registered
9th of 16
by date

Among the 16 studies in Myopia with a site in Germany, this one is the only one that started in 2016, is one of 5 observational ones, and was the 9th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

3 of the 16 studies in Myopia with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Myopia with a site in Germany, or all of them as a file.
02

Study summary

Small Incision Lenticule Extraction (SMILE) was introduced in 2011 using the VISUMAX femtosecond laser (Carl Zeiss Meditec, Jena, Germany). It is designed for correction of myopia and myopic astigmatism.

It involves the creation of a corneal tissue disk called lenticule and its extraction through a minimally invasive incision, utilizing only a femtosecond laser. This enables rapid visual recovery with very little discomfort to the patient.

This observational case series monitors visual and refractive outcomes of myopic correction for more than -7.75 D.

It is to

  • gather long-term results and refractive stability
  • detect rare complications or side-effects
  • evaluate the efficacy in a large number of patients
03

Conditions studied

  • Myopia
  • High Myopia

Browse trials for

Keywords

  • Myopia
  • Refractive Surgery
  • Small Incision Lenticule Extraction
  • SMILE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients with myopia more than -7.75 D seeking refractive surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults
  • myopia more than -7.75 D
  • refractive stability more than 1 year

Exclusion criteria

Exclusion Criteria:

  • corneal irregular astigmatism
  • ectatic conditions
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1

    SMILE - Correction of eyes with myopia of more than -7.75 D

    Other: Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)

Interventions

  • OtherSmall Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)

    Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser

    Also known as: RelaxSmile

06

What researchers measure

Primary outcomes

  1. Subjective Distance Refraction

    Subjective Refraction

    Time frame: 1 year

  2. Distance Visual Acuity

    Visual Acuity sine and cum correctione

    Time frame: 1 year

Secondary outcomes

  1. Tectonic stability as assessed by Pentacam

    Corneal tectonic stability post surgery as assesed by Scheimpflug-Tomography

    Time frame: 1 year

  2. Epithelial thickness map in Optical coherence tomography

    Change of Thickness of epithelium pre and post surgery

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Center for Refractive Surgery
    Münster, North Rhine-Westphalia 48145, Germany
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2016 (actual). Primary completion is estimated for Nov 2029, 166 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Oct 1, 2019
StartActual
Jan 2016
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Center for Refractive Surgery · Münster, Germany
Show 1 removed
  • Center for Refractive Surgery · Münster, Germany
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added, 1 site removed
    Show site
    • Center for Refractive Surgery · Münster, Germany
    Show 1 removed
    • Center for Refractive Surgery · Münster, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04110067
Lead sponsor
Suphi Taneri
Responsible party
Suphi Taneri (Director, St. Franziskus Hospital) — Sponsor-investigator
First posted
Oct 1, 2019
Start date
Jan 2016
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Suphi Taneri, MD
Contact
taneri@refraktives-zentrum.de
+492519877890
Anika Förster, M.Sc.
Contact
foerster@refraktives-zentrum.de
+492519877890
Suphi Taneri, MD
study chair · Center for Refractive Surgery Muenster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion